Current Issue
Subscribe
The release of two new oral medications marks another significant advance in the fight against hepatitis C.
Boceprevir and telaprevir were approved for treatment of hepatitis C in May 2011.
Potential candidates for the new hepatitis C drugs will need to consider the drugs’ price, which will be added to the already steep cost of interferon and ribavirin.
1-2%
of people in the US have von Willebrand disease, the most common bleeding disorder.